(NASDAQ: EOLS) Evolus's forecast annual revenue growth rate of 30.35% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Evolus's revenue in 2025 is $266,274,000.On average, 3 Wall Street analysts forecast EOLS's revenue for 2025 to be $22,346,292,607, with the lowest EOLS revenue forecast at $22,185,418,122, and the highest EOLS revenue forecast at $22,566,302,772. On average, 3 Wall Street analysts forecast EOLS's revenue for 2026 to be $29,470,552,413, with the lowest EOLS revenue forecast at $28,289,746,410, and the highest EOLS revenue forecast at $30,178,272,974.
In 2027, EOLS is forecast to generate $37,684,434,818 in revenue, with the lowest revenue forecast at $35,831,135,316 and the highest revenue forecast at $38,698,897,876.